Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum-Containing Doublet in Chemotherapy-Naive Subjects With Stage IV Adenocarcinoma of the Lung (FLAIR)
Conditions
Interventions
Farletuzumab
Placebo
+4 more
Locations
93
United States
Ironwood Cancer and Research Center
Chandler, Arizona, United States
Arizona Center for Hematology Oncology
Glendale, Arizona, United States
Providence Health System
Beverly Hills, California, United States
Cancer Care Associates of Fresno Medical Group, Inc.
Fresno, California, United States
Medical Oncology Hematology
Gilroy, California, United States
California Cancer Care, Inc.
Greenbrae, California, United States
Start Date
June 27, 2011
Primary Completion Date
December 15, 2012
Completion Date
November 1, 2013
Last Updated
August 20, 2020
NCT04046614
NCT01958372
NCT01259089
NCT02466568
NCT01557959
NCT02715102
Lead Sponsor
Morphotek
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions